HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MicroBiome Therapeutics LLC

www.numehealth.com

Latest From MicroBiome Therapeutics LLC

Scrip Asks… Is The Microbiome Hype Or Happening?

Buzz is growing over the potential of research on the microbiome to yield new therapeutics. Scrip asked pharma, academics and venture capitalists how long it might take to see results, what breakthroughs are needed and which therapeutic areas might benefit first. Vote to tell us what you think.

Strategy Innovation

Microbiotica: Wellcome Spin-Out Exploits Unique Microbe Collection

Emerging Company Profile: Microbiotica, a UK biotech spin-out from the Wellcome Trust Sanger Institute announced late last year, says it has unique capabilities in culturing and sequencing the human bacterial microbiome that will be of use to develop bacterial mixes for therapeutic use.

Commercial StartUps and SMEs

Sanger Institute Spin-Out Microbiotica To Evaluate Bacterial Mixes

The UK Wellcome Trust Sanger Institute’s latest spin-out has received start-up funding to exploit more than six years of gut bacterial genome sequencing in order to develop novel bacteria-based therapies for a range of diseases.

StartUps and SMEs Financing

Fat To Water: Big Hopes For Microbiome Approaches To Obesity and Metabolic Disease

Finding the right microbial balance in the gut may be the way of the future for treatment of conditions like obesity and diabetes. That’s where some notable medical futurists are looking and where some early commercial clinical trials are underway. In addition to all the usual uncertainties about new ideas in therapeutics, this idea has an extra question mark: what will the regulatory model be?

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
    • Nutraceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Metabolic Disorders
  • Alias(es)
  • NuMe Health LLC
  • NuMe Health LLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • MicroBiome Therapeutics LLC
  • Senior Management
  • Dean P Stull, PhD, Pres. & CEO
    Mark Heiman, VP, Rsch. & CSO
    Justin Peno, Dir., Bus. Dev.
  • Contact Info
  • MicroBiome Therapeutics LLC
    Phone: (303) 589-9472
    1441 Canal St.
    New Orleans, LA 70112
    USA
UsernamePublicRestriction

Register